|
Array BioPharma Inc. and AstraZeneca today announced plans for two additional randomized Phase 2 trials for AZD6244 (ARRY-886)
BOULDER, CO, USA | May 15, 2008 | Array BioPharma Inc. (NASDAQ: ARRY) and AstraZeneca (NYSE: AZN) today announced plans for two additional randomized Phase 2 trials for AZD6244 (ARRY-886). The trials, which will begin during the second half of 2008, will test AZD6244 in combination with a cytotoxic chemotherapeutic agent; one trial will be in melanoma patients and the other in non small cell lung cancer patients. These plans are based upon AZD6244's activity as a single agent in previous monotherapy Phase 2 trials and on data from multiple preclinical studies. The data from these earlier clinical trials will be presented at the forthcoming American Society of Clinical Oncology Annual Meeting.
"We believe that AZD6244 holds promise for cancer patients and we look forward to the initiation of these additional Phase 2 trials," said John Yates, M.D., Chief Medical Officer, Array BioPharma. "We're pleased to be working with AstraZeneca's experienced oncology team and are excited about their strong commitment to bringing this novel treatment to people with cancer."
About AZD6244 (ARRY-886)
AstraZeneca acquired exclusive worldwide rights to AZD6244 and certain second-generation compounds for all oncology indications in December 2003. Array was responsible for filing the IND and conducting the Phase 1 clinical testing of AZD6244. AstraZeneca is responsible for all other aspects of clinical development and commercialization. Array retains the rights to all therapeutic indications outside of oncology for compounds not selected by AstraZeneca as part of the collaboration.
AZD6244 is an anti-cancer drug in Phase 2 development in a range of tumors. It is a small molecule inhibitor that targets a key position in the Ras/Raf/MEK/ERK signalling pathway. This pathway is implicated in the development and progression of cancers.
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory diseases and pain. Our proprietary drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target proteins and are aimed at large market opportunities. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas. For more information on Array, please go to www.arraybiopharma.com.
SOURCE: Array BioPharma Inc. |
